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ABSTRACT
Introduction: Respiratory syncytial virus (RSV)
infection causes respiratory disease throughout life,
with infants and the elderly at risk of severe disease
and death. RSV001 is a phase 1 (first-in-man), open-
label, dose-escalation, clinical trial of novel genetic
viral-vectored vaccine candidates PanAd3-RSV and
modified vaccinia virus Ankara (MVA)-RSV. The
objective of RSV001 is to characterise the (primary
objective) safety and (secondary objective)
immunogenicity of these vaccines in healthy younger
and older adults.
Methods and analysis: Heterologous and
homologous ‘prime’/boost combinations of PanAd3-
RSV and single-dose MVA-RSV are evaluated in healthy
adults. 40 healthy adults aged 18–50 years test one of
four combinations of intramuscular (IM) or intranasal
(IN) PanAd3-RSV prime and IM PanAd3 or IM MVA-
RSV boost vaccination, starting at a low dose for
safety. The following year an additional 30 healthy
adults aged 60–75 years test either a single dose of IM
MVA-RSV, one of three combinations of IN or IM
PanAd3-RSV prime and PanAd3-RSV or MVA-RSV
boost vaccination used in younger volunteers, and a
non-vaccinated control group. Study participants are
self-selected volunteers who satisfy the eligibility
criteria and are assigned to study groups by sequential
allocation. Safety assessment includes the daily
recording of solicited and unsolicited adverse events
for 1 week after vaccination, as well as visit (nursing)
observations and safety bloods obtained at all
scheduled attendances. Laboratory measures of RSV-
specific humoral and cellular immune responses after
vaccination will address the secondary end points. All
study procedures are performed at the Centre for
Clinical Vaccinology and Tropical Medicine (CCVTM),
Oxford, UK.
Ethics and dissemination: RSV001 has clinical trial
authorisation from the Medicines and Healthcare
Products Regulatory Agency (MHRA) and ethics
approval from NRES Berkshire (reference 13/SC/0023).
All study procedures adhere to International Conference
on Harmonisation (ICH) Good Clinical Practice
guidelines. The results of the trial are to be published
in peer-reviewed journals, conferences and academic
forums.
Trial registration number: NCT01805921.
INTRODUCTION
Respiratory syncytial virus (RSV), is a major
global health problem. RSV causes respira-
tory infections throughout life, with infants
in the first months of life, severely immune-
compromised adults and the elderly espe-
cially susceptible to developing severe lower
respiratory tract disease or death.
Primary RSV infection is common in the
first year of life and usually mild.1 Severe
disease, manifesting as a compromise of
breathing or feeding, warrants hospital
admission in 2–3% of primary infections
where the care is supportive until the
immune response controls the infection to
restore normal function.2 3 Passive immune
prophylaxis with monoclonal antibody can
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reduce hospitalisation rates in infants with predisposing
conditions for developing severe disease, but the major-
ity of RSV-bronchiolitis admissions are from otherwise
healthy infants born at term.4 5 Severe bronchiolitis
accounts for 10% all annual admissions to paediatric
intensive care units in the UK3 6 and access to mechan-
ical ventilation has maintained low mortality rates from
RSV disease in industrialised healthcare settings.7 8
Globally, RSV infection is the second most common
cause of death in infants after 1 month and before
1 year of age9 and children under 5 years of age are
responsible for an estimated 34 million lower respiratory
tract infections, 3.4 million hospitalisations and up to
200 000 deaths worldwide each year.10 RSV infection in
infancy has also been associated with the development
of wheeze and possibly asthma later in later years, with
accumulating evidence for causality.11 12 Reinfection
occurs throughout life and even possible within the
first year of life.13 Healthy adults experience mild RSV
infections14 15 but severe immune-compromise can risk
severe lower respiratory tract disease.16 An aging
immune system and comorbidities in the elderly are
factors thought to increase rates of hospitalisation and
mortality from RSV to comparable estimates of disease
burden to seasonal influenza.17–20
There is no licenced vaccine and RSV remains a
high priority for vaccine development. The disastrous
formalin-inactivated RSV (FI-RSV) vaccine trial in the
in 1960s resulted in the death of two infants following
natural exposure and a 16-fold rise in hospitalisation
rate in other vaccine recipients.21–24 This tragedy,
together with an incomplete understanding of the
immune response and immune correlates of protec-
tion to natural disease, has made RSV vaccine develop-
ment especially challenging. Concerns about vaccine
primed immunopathology to natural exposure in
RSV-naïve infants and inadequate immunogenicity in
the elderly has focused RSV subunit vaccine develop-
ment as maternal vaccines.25–28 Live-attenuated vaccine
candidates have been in clinical evaluation for over
50 years and appear safe in seronegative infants, but
remain troubled by genetic instability, limited immuno-
genicity and vaccine virus shedding with secondary
infection.29–32
In this first-in-man clinical trial, designated RSV001,
we characterise the safety and immunogenicity of novel
viral-vectored vaccines used to deliver RSV antigen in
healthy adult volunteers. Heterologous and homolo-
gous prime/boost combinations of genetically modified
chimpanzee derived adenovirus and modified vaccinia
virus Ankara (MVA) viral vectors have been used as
biological platforms in the safe delivery of vaccine
antigen for several infectious diseases and cancer,
including safe use in infants.33–36 In RSV001, the
replication-defective adenoviral vector PanAd3 and
MVA encode 3 RSV proteins as antigen for the induc-
tion of humoral and cellular RSV-specific immune
responses.
MATERIALS AND ANALYSIS
Objectives and end points of the clinical trial
The objectives of the RSV001 trial are to characterise
the safety and tolerability (primary objective) and
immunogenicity (secondary objective) of different com-
binations of PanAd3-RSV and MVA-RSV in healthy adults
aged 18–50 and 60–75 years. The primary and secondary
end points are listed in table 1.
Intervention
The generation of the PanAd3 vector and PanAd3-RSV
and MVA-RSV vaccines, and results of preclinical evalu-
ation, are described in more detail elsewhere.37–40
Vaccine construct
PanAd3-RSV and MVA-RSV are replication-defective
genetically modified organisms (GMOs) for the deliv-
ery of RSV protein as vaccine antigen. The genetic
insert for PanAd3 and MVA viral vectors is the same
codon-optimised single synthetic DNA fragment encod-
ing the RSV proteins F (fusion protein, F0ΔTM), N
(nucleocapsid protein) and M2–1 (matrix protein),
shown schematically in figure 1. Deletion of the E1
and E4 loci of PanAd3 renders the adenovirus replica-
tion defective, and MVA cannot naturally replicate in
mammalian cells. The F0ΔTM protein is a truncated
soluble antigen (lacking the trans-membrane region of
the full length F protein) detectable in the cell super-
natant while the N and M2–1 proteins are retained
intracellularly after transfection of the vaccine virus.
Product safety and characterisation testing included
sterility, endotoxins, residual host cell DNA and pro-
teins, genome sequencing and extensive screening for
extraneous virus contamination. For PanAd3, the
absence of replication-competent adenovirus was veri-
fied and potency of the product quantified using anti-
hexon immune staining and quantitation of total
vector particle concentration. Testing of the MVA-RSV
vaccine product included virus titre, identity, purity and
expression of RSV transgene. Clinical grade
PanAd3-RSV and MVA-RSV vaccine products were man-
ufactured under Good Manufacturing Practice (GMP)
conditions by Advent (Italy) and Impfstoffwerk
Dessau-Tornau (Germany). Vaccines are stored on site
at ≤−60°C until use.
Preclinical data from PanAd3-RSV and MVA-RSV
Cotton rats, mice and calves were used to generate pre-
clinical safety and immunogenicity data from
PanAd3-RSV and MVA-RSV.37–39 These included human
and bovine RSV challenge experiments in cotton rats
and calves respectively, and included non-vaccinated and
FI-RSV vaccinated controls. Seronegative calves were
used as a translational model for seronegative infants
who are at the greatest risk of developing severe RSV
disease and FI-RSV associated immunopathology follow-
ing natural exposure. In these experiments we could not
detect any FI-RSV Th2-associated immunopathology
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after challenge. All combinations of vaccine were
capable of protection from viral replication in the lower
respiratory tract, and heterologous combinations of
vaccine (including intra-nasal PanAd3-RSV prime) con-
ferred complete restriction of viral replication in the
upper respiratory tract as well. Based on data from the
bovine challenge model,37 four heterologous and homo-
lgous prime/boost combinations were selected for the
RSV001 trial in humans.
Clinical trial design
RSV001 is an open label, dose-escalation, single-site,
phase 1 (first-in-man) clinical trial of PanAd3-RSV and
MVA-RSV in healthy adult volunteers. 40 healthy volun-
teers aged 18–50 years are enrolled in 2013. After an
interim analysis of safety and immunogenicity data,
the following year an additional 30 healthy adults aged
60–75 years are required to assess safety and immuno-
genicity in older adults, as development of the vaccine
towards a population in need of protection to severe
RSV disease.
Setting and current progress
RSV001 is being performed at the Centre for Clinical
Vaccinology and Tropical Medicine (CCVTM), Oxford,
UK. Clinical procedures started in May 2013 and clinical
data collection is expected to complete in August 2015.
Laboratory analyses are expected to continue for a
period up to 3 years from this date.
Study groups
RSV001 contains a total of nine study groups; seven
groups are either heterologous or homologous prime/
boost combinations of PanAd3-RSV and MVA-RSV, one




Solicited and unsolicited symptoms
recorded daily for 1 week after each
vaccine dose
Oral temperature
Solicited symptoms: headache, nausea and/or vomiting,
malaise, myalgia and arthralgia
Local injection site adverse events: pain and/or
tenderness, erythema, induration and swelling
Local nasal site adverse events: pain and/or tenderness,
irritation and discharge
Any other event not listed above (unsolicited symptoms)
Nursing observations obtained at all
visit attendances
Resting heart rate, resting respiratory rate, systolic and
diastolic blood pressure and oral temperature
Safety bloods obtained at scheduled
visit attendances
Haematology: haemoglobin, total white cell count,
platelet count, haematocrit, red cell count, mean cell
volume, mean haemoglobin, mean haemoglobin
concentration, neutrophil count, lymphocyte count,
monocyte count, eosinophil count and basophil count
Biochemistry: sodium, potassium, urea, amylase, C
reactive protein, creatinine, bilirubin, alanine
transaminase, alkaline phosphatase and albumin
Secondary objective:
vaccine immunogenicity
Antibody response to vaccination Serum antibody response to RSV F antigen
Serum antibody response capable of RSV neutralisation
Cellular immune response to
vaccination
Quantification of circulating vaccine-induced antibody
secreting B-cells (IgA and IgG) against RSV F antigen
Quantification of circulating vaccine-induced T-cell
responses against RSV antigens F, N and M2–1
Exploratory immunology Nasal and salivary antibody response to vaccination
CD4+ and CD8+ T-cell subset response to vaccination
Cytokine response to vaccination
Gene expression changes after vaccination
Any further exploratory immunology to detect
vaccine-related immune responses
RSV, respiratory syncytial virus.
Figure 1 The single DNA fragment insertion for the
expression of RSV proteins by PanAd3 and MVA. The same
codon-optimised DNA fragment was inserted into
replication-defective PanAd3 and MVA viral vectors. After
transfection into a mammalian cell, cleavage of a Foot and
Mouth Disease Virus 2A region releases a soluble truncated F
protein while the N and M2-1 proteins remain intracellular.
MVA, modified vaccinia virus Ankara; RSV, respiratory
syncytial virus.
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group is single-dose MVA-RSV and one group is a non-
vaccinated control arm (see table 2). Adults have robust
RSV-specific immune responses from repeated exposure
and the term ‘prime’ is inherited from clinical trials in
antigen naïve populations. Here the term ‘prime’ is
used to denote the first dose of vaccine, and ‘boost’ the
second dose of vaccine.
Adults aged 18–50 years test one of four combinations
of prime/boost (study groups 1–4) selected from pre-
clinical data in animal challenge experiments, and
include an intranasal route for the adenoviral vectored
prime dose. Within each study group, two individuals
test a low-dose vaccine before the remaining volunteers
receive high-dose vaccine.
Adults aged 60–75 years have a non-vaccinated control
group, a single high-dose MVA-RSV group and three
groups testing different combinations of prime/boost
vaccine at high dose (study groups 5–9). The vaccine
strategies for older adults are selected from the interim
analysis of safety and immunogenicity data from study
groups 1–4 in younger adults.
Dose escalation
The trial commences with the low-dose vaccinations in
younger adults. One volunteer receives IM PanAd3-RSV
and one volunteer IN PanAd3-RSV and are observed for
any adverse events (AEs) for a minimum of 48 h before
any more volunteers receive low-dose prime vaccine.
Formal assessment of all safety data and approval from
the independent data safety monitoring committee
(DSMC) is required before dose escalation and contin-
ued (booster) low-dose vaccinations. Halting rules for
dose-escalation includes the occurrence of a serious
adverse reaction (SAR) or if two participants experience
a severe AE (grade 3) that is clinically significant with a
reasonable possibility of being related to the vaccine. If
the trial is halted, study drug is not administered to any
additional subject and enrolment stops until the DSMC
has reviewed the events. Dose and group size escalation
in RSV001 are shown schematically in figure 2. All vac-
cines administered to groups 6–9 are at high dose.
Vaccination procedures
Doses of vaccine are prepared by diluting the concen-
trated product with 0.9% sterile saline solution to the
required concentration and volume. Low-dose and high-
dose PanAd3-RSV is 5×109 and 5×1010 viral particles
(vp), respectively. Low-dose and high-dose MVA-RSV is
1×107 and 1×108 plaque forming units (pfu), respect-
ively. PanAd3-RSV is given either by intramuscular injec-
tion of 0.5 mLs vaccine product to the non-dominant
deltoid muscle, or by intra-nasal spray of 0.15 mLs
volume to each nostril in the sitting position using a
syringe attached to an LMA MAD Nasal needle-free
drug delivery system (LMA, San Diego, California, USA).
MVA-RSV is administered by intra-muscular (IM) injec-
tion of 0.5 mLs vaccine product to the non-dominant
deltoid muscle only.
Volunteers are required to wait and be observed for
1 h after the administration of each vaccine dose for
signs of anaphylaxis. All clinical staff are trained and can
provide evidence of competency in the acute manage-
ment of anaphylaxis reactions and epinephrine is avail-
able at all times of vaccine administration and
subsequent observation. This is detailed in relevant
standard operating procedures (SOPs). The nearest
medical ward is in the adjoining corridor and nearest
Accident and Emergency Department is at the Oxford
Radcliffe Hospital, Oxford University Hospitals NHS
Trust, which is within minutes by ambulance transfer.
GMO considerations
PanAd3-RSV and MVA-RSV are used in accordance with
GMO (Contained Use) Regulations 2000. Vaccine admi-
nistered by intramuscular injection has the site of inocu-
lation covered with a dressing after immunisation. This
should absorb any virus that may leak out through the
needle track and the dressing is removed from the
Table 2 The nine study groups in RSV001
N volunteers Prime vaccine Boost vaccine Prime/boost interval
2013/14—healthy adults aged 18–50 years
Group 1 10 IM PanAd3-RSV IM MVA-RSV 8 weeks
Group 2 10 IM PanAd3-RSV IM PanAd3-RSV 4 weeks
Group 3 10 IN PanAd3-RSV IM MVA-RSV 8 weeks
Group 4 10 IN PanAd3-RSV IM PanAd3-RSV 8 weeks
2014/15—healthy adults aged 60–75 years
Group 5 6 None None Not applicable
Group 6 6 IM MVA-RSV None Not applicable
Group 7 6 IM PanAd3-RSV IM PanAd3-RSV 4 weeks
Group 8 6 IN PanAd3-RSV IM MVA-RSV 8 weeks
Group 9 6 IM PanAd3-RSV IM MVA-RSV 8 weeks
PanAd3-RSV prime can be administered by IM injection or IN spray. All boost vaccines are given by IM injection. The first two volunteers in
groups 1–4 receive a low-dose of vaccine; all other volunteers in RSV001 receive the high-dose of vaccine. The prime/boost interval is
8 weeks for all study groups who receive two doses of vaccine except for the double prime groups 2 and 7 who are vaccinated with a 4-week
interval between doses.
IM, intramuscular; IN, intranasal; MVA, modified vaccinia virus Ankara; RSV, respiratory syncytial virus.
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injection site after 30 min and disposed as GMO waste
by autoclaving in accordance with relevant SOPs. Each
volunteer vaccinated with PanAd3-RSV by intranasal
spray remains in the clinic room for 30 min after dosing
to contain any vaccine expelled by sneezing. The
Mucosal Atomization Device (MAD nasal) is disposed as
GMO waste by autoclaving in accordance with the rele-
vant SOPs.
Study procedures and schedules for data collection
A volunteer is considered enrolled at the point of receiv-
ing the first vaccine (prime). For Group five volunteers,
who do not receive a vaccine, enrolment occurs with
completion of the first visit (V1). If a volunteer withdraws
from the study, a newly recruited volunteer may com-
mence the trial in their place. The schedule of research
site attendances, study procedures and data collection for
enrolled volunteers are set out in table 3. In summary;
▸ Volunteers in study groups 1, 3 and 4 are invited to
attend a total of 12 visits over 34 weeks
▸ Volunteers in study group 2 are invited to attend a
total of 11 visits over 30 weeks
▸ Volunteers in study groups 5, 8 and 9 are invited to
attend 13 visits over 52 weeks
▸ Volunteers in study groups 6 and 7 are invited to
attend 12 visits over 52 weeks
Volunteers who report an influenza-like illness during
the study attend an unscheduled visit for the detection
of RSV or other viral infection by PCR on nasal swabs.
This may identify RSV-specific immune responses to
natural infection that could mimic vaccine immunogen-
icity and four unscheduled visits per volunteer are
permitted.
The maximum volume of blood obtained from any
volunteer in study groups 1–4 is 964 mLs from screening
to completion of all subsequent visits inclusive of four
unscheduled visits. In older adults (study groups 5–9)
the maximum volume of blood obtained from any vol-
unteer is 725 mLs from screening to completion of all
subsequent visits inclusive of four unscheduled visits.
DNA and/or serum remaining after the RSV001 analyses
have been performed are, with specific volunteer
consent, to be transferred to the Oxford Vaccine Group
BioBank for future seroepidemiological and other




Potential volunteers are self-selected members of the
public responding to advertisements inviting them to
consider volunteering for the trial. Methods of recruit-
ment include;
▸ Poster advertising throughout local hospitals and
doctor’s surgeries, tertiary education institutions and
Figure 2 Schematic for dose and group size escalation for adults aged 18–50 years, enrolled in 2013. (n=number of
volunteers). At each dose, prime vaccination with IM and IN PanAd3-RSV was performed in one individual and safety assessed
for a minimum of 48 h before the remaining prime vaccinations were administered. Formal DSMC approval was required before
administration of the low-dose booster and high-dose prime vaccinations, and again for the high-dose boost vaccinations. For
older adults aged 60–75 years, enrolled in 2014, there is no low dose of vaccine and no group size escalation. DSMC, data
safety monitoring committee; IM, intramuscular; IN, intranasal; RSV, respiratory syncytial virus.
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UN Any ♦ ♦ ♦ 10
7
*Nasal samples for PanAd3-RSV shedding was performed only in volunteers who received IN PanAd3-RSV prime (groups 3, 4 and 8).
†No RNA samples were taken from the single-dose MVA group (group 6) from V6 onwards.
‡Serum anti-PanAd3 antibody samples at V10 were obtained from volunteers who received IM PanAd3-RSV vaccine at prime and boost (groups 2 and 7).
§There is no V13 time-point for adults aged 18–50 years (study groups 1–4). For each blood sample, the top number is the volume obtained from adults aged 18–50 years (study groups 1–4);
the bottom number is the volume obtained from adults aged 60–75 years (study groups 5–9). In addition to scheduled attendances, each volunteer was allowed a maximum of four unscheduled
visits (UN1, UN2, UN3 and UN4) for reasons of safety or influenza-like illnesses and the detection of RSV infection.
♦Denotes collection of these data at these visits. Each volunteer also attended a screening visit (V0) before enrolment into the study and receives prime vaccine (P) at V1 and boost vaccine (B)
at V6. The prime/boost interval is group dependent. Study groups 2 and 7 do not have a V5 and group 6 does not have a V7. Vaccine continued eligibility tests include an interim medical history
(see temporary exclusion criteria) and urine pregnancy testing.
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▸ Direct mail-out of the study information sheet to
adults whose names and addresses are obtained via
the Electoral register. Those people who have indi-
cated they do not wish to receive postal mail−shots
would have their names removed prior to the
Investigators being given the names and addresses.
The company providing this service is registered
under the Data Protection Act 1998.
▸ Email campaign via representatives of local tertiary
education establishments and local employers and
ask them to circulate posters and link to study website
by email or hard copy.
▸ Oxford Vaccine Centre (OVC) database for healthy
volunteers: Direct email and link to members of the
public who have registered their interest in poten-
tially volunteering for clinical trials conducted by
OVC. This secure database is maintained by OVC and
members of the public registered here have given
consent to have their details recorded and be con-
tacted expressly for this purpose of being notified
when a trial opens for recruitment. They understand
this is not a commitment to volunteering for any trial
they are contacted about.
▸ Media advertising by local media, newspaper and
website advertisement placed in locations relevant for
the target age group with brief details of the study
and contact details for further information.
▸ Website advertising on the OVG website (http://www.
ovg.ox.ac.uk).
▸ Exhibitions using stalls or stands at exhibitions and/
or fairs, such as University Fresher’s Fairs.
▸ Open Exeter: Potential study volunteers identified via
National Health Applications and Infrastructure
Services (NHAIS) who hold the central NHS patient
database (Open Exeter).
Potential volunteers who are interested in study par-
ticipation are able to contact the Oxford Vaccine Group
by telephone, email and website for further information.
If potential volunteers are willing to proceed they are
invited for physician screening, consent and formal
assessment of suitability for the trial.
Informed consent
Consent is obtained from a study physician and each vol-
unteer personally signs and dates the latest approved
version of the informed consent form before any study
specific procedures are performed. Written and verbal
versions of the participant information booklet and
informed consent form are presented to volunteers,
detailing no less than the exact nature of and the ration-
ale for performing the study, the implications and con-
straints of the protocol and the risks and benefits
involved in taking part. It is clearly stated that volunteers
are free to withdraw from the study at any time, for any
reason and that they are under no obligation to give the
reason for withdrawal. Potential volunteers allowed an
adequate time to consider the information from when
they receive it, and the opportunity to question the
researcher, their GP or other independent parties to
decide whether to participate in the study.
Assessment of eligibility
Formal assessment of trial eligibility follows once written
informed consent is obtained. The full inclusion and
exclusion criteria are detailed in box 1. Physician screen-
ing includes;
▸ Recording of volunteer demographics; age, sex, body
mass index, ethnicity, occupation
▸ Assessment of current and past medical history
▸ Physical examination
▸ 12-lead ECG
▸ Blood sampling; routine haematology and biochemis-
try, blood born viruses (HIV, HBV and HCV) and
serum IgA levels
▸ Urine sampling; microscopic haematuria, pyuria or
proteinuria, and pregnancy if appropriate
▸ Registration with The Over-volunteering Prevention
Systems (TOPS) to guard against the potential for
harm that can result from excessive volunteering in
clinical trials and blood donations
▸ GP agreement that they do not know of a reason the
potential volunteer should be excluded, based on
study specific paperwork sent to the GP.
An eligible or enrolled volunteer can have vaccination
deferred if any of the following temporary exclusion cri-
teria apply;
▸ Low-grade febrile illness (oral temperature ≥37.5°C)
▸ Any moderate or severe illness irrespective of tem-
perature, such as diarrhoea, mild upper respiratory
infection
▸ A laboratory AE considered, in the opinion of the
investigator, of requiring of further time and/or
investigation to resolve or stabilise prior to another
dose of vaccine being administered
▸ Receipt of a live vaccine within 4 weeks prior to vac-
cination or a killed vaccine within 7 days prior to
vaccination.
Allocation to study groups
Each volunteer is assigned to a study group by sequential
allocation, and not by choice or by randomisation.
Although RSV001 is not a randomised clinical trial, the
results of volunteer recruitment, enrolment and reten-
tion are reported according to the CONSORT 2010
statement.41
Volunteer compensation
Enrolled volunteers are compensated for their time,
costs incurred and the inconvenience of procedures
based on the following figures:
▸ Travel expenses: £15 per visit
▸ Inconvenience of blood tests: £10 per blood
donation
▸ Inconvenience of nasal sampling: £10 per sample
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▸ Time required for visits: £20 per visit
Four extra visits (designated as unscheduled visits) are
included in the total remuneration for each volunteer
regardless of whether they are used to remove any incen-
tive to report an influenza-like illness during the study.
Volunteers in study group 2, 6 and 7 are compensated
the same as all other volunteers despite having one less
scheduled visit. Remuneration is on a pro rata basis
should a volunteer fail to complete all scheduled visits
and/or study requirements. Each volunteer in study
Box 1 Inclusion and exclusion criteria for RSV001 volunteers
Inclusion criteria—all must be satisfied
1. Volunteer must be willing and able to consent to take part in the clinical trial
2. At the time of enrolment; aged 18–50 years inclusive for study groups 1–4, or aged 60–75 years inclusive for study group 5–9
3. In good health as determine by medical history, physical examination and in the judgement of the study investigators
4. Willing to use effective contraception (if sexually active);
▸ Females: Oral contraceptive pill, contraceptive implant or barrier methods from 1 month prior and for the duration of the study
▸ Males: Barrier contraceptive from V1 until 3 months after the last dose of vaccine
5. Willing to allow his/her General Practitioner and/or Consultant, if appropriate, to be notified of participation in the study
6. Confirmation from the General Practitioner that they are aware of the inclusion and exclusion criteria and are satisfied from their knowl-
edge of the volunteer that they are suitable to enrol
7. Willing to provide their National Insurance/Passport number for the purpose of TOPS registration
Exclusion criteria—none can be satisfied
1. History of any significant organ/system disease that interfere with trial conduct or completion. These include any history of significant
disease in the following;
▸ Cardiovascular disease including congenital heart disease, previous myocardial infarction, valvular heart surgery (or history of
rheumatic fever), previous bacterial endocarditis, history of cardiac surgery (including pacemaker insertion), personal or family
history of cardiomyopathy or sudden death
▸ Respiratory disease such as asthma (excluding childhood asthma not treated in adulthood) and chronic obstructive pulmonary
disease
▸ Endocrine disorders such as diabetes mellitus and Addison’s disease
▸ Significant renal or bladder disease, including a history of renal calculi
▸ Biliary tract disease
▸ Gastro-intestinal disease such as inflammatory bowel disease, abdominal surgery within the last 2 years, coeliac disease and liver
disease
▸ Neurological disease such as seizures and myasthaenia gravis
▸ Metabolic disease such as glucose-6-phosphate dehydrogenase deficiency
▸ Psychiatric illness requiring hospitalisation or depression whose severity is deemed clinically significant by the chief investigator,
consultant or GP
▸ Non-benign cancer, including squamous cell carcinoma, basal cell carcinoma of the skin and cervical carcinoma in situ
▸ Clinically significant contact dermatitis
2. Have any known or suspected impairment or alteration of immune function, resulting from, for example: congenital or acquired
immune deficiency, HIV or symptoms/signs of an HIV-associated condition, autoimmune disease, receipt of immunosuppressive
therapy such as chemotherapy or radiation therapy in the preceding 12 months or long-term corticosteroid therapy, receipt of immuno-
globulin or any blood product transfusion within 3 months of the study start.
3. A vaccination history indicative of; planning to receive another vaccine (other than the study vaccine) within 4 weeks of vaccination, a
history of anaphylaxis reaction to a vaccine, history of allergic disease or reactions likely to be exacerbated by any component of the
vaccine (eg, Kathon), previously having received a recombinant simian or human adenoviral vaccine, previously having received a
recombinant MVA vaccine.
4. Detection of any of the following at screening; IgA deficiency, anti-HIV antibody, hepatitis B surface antigen, anti-HCV antibody, any
other significant abnormalities at the discretion of the study investigator.
5. Known or suspected drug and/or alcohol misuse (alcohol misuse defined as an intake >42 units/week).
6. Nasal septal pathology including; congenital deformities such as an abnormal septum or polyps, previous cauterisation, rhinoplasty or
surgery of any kind, recurrent epistaxis.
7. Scheduled procedures requiring general anaesthesia during the study.
8. Participation in another research study involving an investigational product in the past 12 weeks, or are planning to do so during the
study.
9. Inability, in the opinion of the investigator, to comply with study requirements.
10. Female volunteers who are pregnant, lactating or planning pregnancy during the course of the study.
11. Has donated blood within 4 months before starting the trial, or is intending to donate blood during the trial and up to 12 weeks after
completing the trial.
12. Any other significant disease or disorder which, in the opinion of the investigator, may put the volunteer at risk because of participation
in the study, influence the result of the study or impair the volunteer’s ability to take part on the trial.
HCV, hepatitis C virus; GP, general practitioners; MVA, modified vaccinia virus Ankara; RSV, respiratory syncytial virus.
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groups 1–4 can receive a maximum of £845 and each
volunteer in study groups 5–9 can receive a maximum of
£920.
Assessment of safety
Data collection and severity grading
All safety data are collected and analysed un-blinded
onto an OpenClinica (Community edition) database.
Volunteers report daily on the occurrence and severity
of local and systemic solicited and unsolicited AEs for
1 week after vaccination. Severity grading is described in
table 4. Visit observations (pulse, respiratory rate, tem-
perature and blood pressure) measures from every visit
are graded as described in table 5. Haematological and
biochemical safety blood measures are obtained at all
scheduled attendances and graded according to modi-
fied Federal Drug Administration (FDA) and Division of
AIDS (DAIDS) criteria, set out in table 6. A nasal swab
for the detection of vaccine virus shedding is performed
3 days after prime for volunteers in groups 3, 4 and 7
(IN PanAd3-RSV prime).
Safety data monitoring
Continuous safety monitoring occurs throughout the
trial by the study team with oversight from the DSMC.
The DSMC is independent and reviews safety data
throughout the study according to a prespecified DSMC
charter. The DSMC charter is written in accordance with
DAMOCLES guidance and agreed on before the trial
starts.42 Formal approval from the DSMC is required
prior to the administration of the low-dose boost vaccine
and before dose escalation to high-dose prime, and
again before high-dose boost (see figure 2). The
outcome of each DSMC review is communicated directly
to the study investigators and documentation of all
reviews are kept in the trial master file. The Chair of the











vomiting, malaise, myalgia and
arthralgia and any other
systemic symptom
0 Absence or resolution of symptom
1 Awareness of symptom but tolerated; transient or mild
discomfort, little/no medical intervention required
2 Discomfort enough to cause limitation of usual activity; some
medical intervention or therapy required





Tenderness/pain at the site of
injection
0 None
1 Painful to touch; easily tolerated
2 Painful when the limb is moved; interferes with daily activity
3 Severe pain at rest; prevents daily activity
Redness and induration at the
site of injection
0 0–2 mm maximal diameter reaction
1 3–50 mm maximal diameter reaction
2 51–100 mm maximal diameter reaction
3 >100 mm maximal diameter reaction
Swelling at the site of injection 0 No visible reaction
1 1–20 mm maximal diameter reaction
2 21–50 mm maximal diameter reaction




Nasal tenderness/pain 0 None
1 Painful on touch only and minimal
2 Painful without touch, moderate severity
3 Painful without touch, severe and interferes with smell
Nasal irritation 0 None
1 Mild irritation only
2 Moderate irritation, distracting
3 Severe irritation, disturbs rest or interferes with normal activity
Nasal discharge 0 None
1 Mild discharge
2 Moderate discharge, readily controlled
3 Severe discharge, interferes with normal activity
Adverse events are graded as 0 (normal), 1 (mild), 2 (moderate) or 3 (severe) from the recorded outcome measures in this table.
IM, intramuscular; IN, intranasal.
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DSMC can also be contacted for advice where the chief
investigator feels independent advice or review is
required.
AE definitions and reporting
International Conference on Harmonisation (ICH) defi-
nitions are used for AEs, adverse reactions (ARs), severe
AEs (SAEs), SARs and suspected unexpected SARs
(SUSARs). A medically qualified individual must deter-
mine the relationship of each AE to the vaccine as
either ‘related to the vaccine’ (reasonable temporal
sequence and not reasonably attributed to another
cause) or ‘not related to the vaccine’. Each AE should
be recorded to represent a single diagnosis. Changes in
laboratory values are only considered to be AEs if they
are judged to be clinically significant, for example, if
some action or intervention is required. It is left to the
investigator’s clinical judgment whether or not an AE is
of sufficient severity to require the volunteer’s removal
from treatment. A volunteer may also voluntarily with-
draw from treatment due to what he or she perceives as
an intolerable AE. If either of these occurs, the volun-
teer must undergo an end of study assessment and be
given appropriate care under medical supervision, by
referral to their GP, until symptoms cease or the condi-
tion becomes resolved or is stable. All SAEs and SUSARs
must be recorded and reported to the DMSC chair and
sponsor within 24 h of discovery or notification of the
event. Fatal or life-threatening SUSARs must be reported
within 7 days and all other SUSARs within 15 days. Any
additional relevant information should be sent within
8 days of the report.
Pregnancy
Although not AEs, pregnancies are reportable events.
Should a volunteer become pregnant during the trial
the vaccination is discontinued. Any pregnancy occur-
ring during the clinical study and the outcome of the
pregnancy is recorded and followed up for congenital
abnormality or birth defect. Pregnancy notification and
follow-up reports are provided to the DSMC Chair.
Trial monitoring
Clinical Trials Research Governance (CTRG), University
of Oxford, will perform monitoring according to ICH
Good Clinical Practice (GCP). Following written SOPs,
the monitors verify that the clinical trial is conducted
and data are generated, documented and reported in
compliance with the protocol, GCP and the applicable
regulatory requirements.
Assessment of immunogenicity
All laboratory assays and data analyses are performed
blinded. A summary of the planned assays is listed below
and in tables 1 and 3.
▸ Serum antibody response to RSV F antigen
▸ Serum antibody response capable of RSV-
neutralisation
▸ Quantification of circulating vaccine-induced anti-
body secreting B-cells (IgA and IgG) against RSV F
antigen
▸ Quantification of circulating vaccine-induced T-cell
responses against RSV antigens F, N and M2–1
▸ Any further exploratory immunology to detect
vaccine-related immune responses.
Statistics and analysis plan
Analyses are descriptive in nature; the purpose of the
study is to characterise the safety and immunogenicity of
PanAd3-RSV and MVA-RSV in healthy adults. There are
no prespecified hypotheses on which to power the study.
No formal sample size calculations are performed, as
the sample sizes are standard to assess phase 1 stage
product safety and tolerability.
Summary statistics are calculated for safety and
immunogenicity end points without imputation for
missing data. The Centre for Statistics in Medicine
(CSM) writes a detailed statistical analysis plan before
any data is examined. Interim study reports for study
groups 1–4 and 5–9 are generated to examine safety and

















































Adverse events are graded as 0 (normal), 1 (mild), 2 (moderate)
or 3 (severe) from the recorded outcome measures in this table.
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select immunogenicity data 1 month after the last dose
of vaccine in each age group.
Regulatory approvals and trial registration
Clinical Trials Authorisation is granted from the
Medicines and Healthcare Products Regulatory Agency
(MHRA, 07/01/2013) and University of Oxford Genetic
Modification Safety Committee (GSMC reference
GM462.11.64, 21/01/2013). Research Ethics Committee
(REC) approval, and amendments, is granted (NRES
Berkshire reference 13/SC/0023, 08/03/2013). Local
site and NHS R&D approvals are granted (23/04/2013).
RSV001 is registered with clinicaltrials.gov (ref
NCT01805921) and EudraCT (ref 2011–003 589–34).
The final protocol is V.6.1 (dated 24 September 2014).
ETHICS AND DISSEMINATION
Ethical and safety considerations
The Investigator ensures the study is conducted in
accordance with the principles of the current version of
the Declaration of Helsinki, and that RSV001 is con-
ducted in full conformity with relevant regulations and
with the current version of the ICH guidelines for GCP
(CPMP/ICH/135/95). The trial staff ensure that the
volunteer’s anonymity is maintained. The study complies
with the Data Protection Act, which requires data to be
anonymised as soon as it is practical to do so, and all
documents are stored securely and only accessible by
trial staff and authorised personnel.
Potential risks and benefits of taking part
The risks of phlebotomy (pain and bruising) and
common AEs after vaccination are explained to each
potential volunteer before vaccination. The first-in-man
nature of the PanAd3 adenoviral vector, used here as
PanAd3-RSV, and the first MVA-RSV formulation draws
on safety data derived from these vaccines in preclinical
evaluation and from similar adenoviral-vectored and
MVA-vectored vaccines used in humans against other
infectious diseases. In particular, the absence of any
enhanced respiratory disease (ERD) associated with
FI-RSV immunopathology in animal challenge experi-
ments and the independent assessment of preclinical
data by the MHRA. Furthermore, all adults have had
prior exposure to RSV and this was a major protective
factor against developing ERD in the FI-RSV trial.43 44 It
is made clear that taking part in RSV001 cannot be
assumed to have any benefit to study volunteers in pro-
tection to severe RSV infection. The only direct benefits
are the investigation of their general health and altruis-
tic satisfaction in supporting the clinical development of
these vaccines.
Blood volumes
The maximal total blood volume taken over the total
duration of the trial is within current National Health
Service Blood and Transplant (NHSBT) allowances for a
blood donation of 470 mLs every 12 weeks for males and
every 16 weeks for females over the duration of the trial.
As a further precaution, potential volunteers are
excluded if donated blood within 4 months before









Haemoglobin change from baseline (g/dL) <1.5 1.5–2.0 2.1–5.0 >5
Total white cell count (×109/L): elevated 10.8–15.0 15.1–20.0 20.1–25.0 >25.0
Total white cell count (×109/L): depressed 2.5–3.5 1.5–2.4 1.0–1.4 <1.0
Neutrophil count (×109/L) 1.5–2.0 1.0–1.4 0.5–0.9 <0.5
Platelet count (×109/L) 125–140 100–124 25–99 <25
Biochemistry
Sodium (mmol/L): hyponatraemia 132–134 130–131 125–129 <125
Sodium (mmol/L): hypernatraemia 144–145 146–147 148–150 >150
Potassium (mmol/L): hypokalaemia 3.5–3.6 3.3–3.4 3.1–3.2 <3.1
Potassium (mmol/L): hyperkalaemia 5.1–5.2 5.3–5.4 5.5–5.6 >5.6
Urea (mmol/L) 8.2–8.9 9.0–11 >11 RRT
Creatinine (µmol/L) 132–150 151–176 177–221 >221 or RRT
ALT or AST (IU/L) 1.1–2.5×ULN 2.6–5.0×ULN 5.1–10×ULN >10×ULN
Bilirubin (µmol/L): with increased ALT/AST 1.1–1.25×ULN 1.26–1.5×ULN 1.51–1.75×ULN >1.75×ULN
Bilirubin (µmol/L): with normal ALT/AST 1.1–1.5×ULN 1.6–2.0×ULN 2.0–3.0×ULN >3.0×ULN
Alkaline phosphatase (IU/L) 1.1–2.0×ULN 2.1–3.0×ULN 3.1–10×ULN >10×ULN
Amylase (IU/L) 1.1–1.5×ULN 1.6–2.0×ULN 2.1–5.0×ULN >5.0×ULN
Albumin (g/L): hypoalbuminaemia 28–31 25–27 <25 NA
C reactive protein (mg/L) 11–30 31–100 101–200 >200
ALT, alanine transaminase; AST, aspartate transaminase; NA, not applicable; RRT, renal replacement therapy; ULN, upper limit of normal.
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entering the trial, or were planning to donate blood
during the trial or within 12 weeks after the final visit.
Haemoglobin measures are obtained at every visit and
study investigators monitor changes in haemoglobin,
with all data communicated to the DSMC for independ-
ent assessment. For adults aged 60–75 years, the total
blood volume is reduced in response to the older age
range and potential for slower recovery of haemoglobin
due to phlebotomy.
Volunteer compensation
Volunteers are not paid to take part but are compen-
sated for any cost and inconvenience with volunteering
to take part in the trial. The tariff for each procedure,
published here, affords accountability of the final com-
pensation sum and allows for pro rata compensation for
volunteers who do not complete all the study require-
ments. All four unscheduled visits are compensated, irre-
spective of whether they are needed, to remove any
incentive to report an influenza-like illness during the
trial. As volunteers cannot choose which study group to
enter, but consent to join to any group, the omitted
visits in some groups are compensated for in any case.
Publication
The investigators have access to all data and co-ordinate
the dissemination of data from the RSV001 clinical trial.
All publications (eg, manuscripts, abstracts, oral/slide
presentations, book chapters) based on this study are
reviewed by each subinvestigator and by the sponsor
prior to submission. Study volunteers are not given indi-
vidual immunogenicity results but have the overall
results of the clinical trial communicated to them dir-
ectly by way of published material.
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